This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kahl, P. Articles by Buettner, R. Search for Related Content PubMed PubMed Citation Articles by Kahl, P. Articles by Buettner, R.

Androgen Receptor Coactivators Lysine-Specific Histone Demethylase 1 and Four and a Half LIM Domain Protein 2 Predict Risk of Prostate Cancer Recurrence

¹ Institute of Pathology and ² Department of Urology, University Hospital Bonn Medical School; ³ Department of Urology, Evangelische Kliniken Bonn GmbH, Bonn, Germany; and ⁴ Center for Clinical Research, University of Freiburg Medical School, Freiburg, Germany

Requests for reprints: Philip Kahl, Institute of Pathology, University Hospital Bonn Medical School, Sigmund-Freud-Strasse 25, D-53127 Bonn, Germany. Phone: 49-228-287-6488; E-mail: philip.kahl{at}ukb.uni-bonn.de.

Prostate cancer biology varies from locally confined tumors with low risk for relapse to tumors with high risk for progression even after radical prostatectomy. Currently, there are no reliable biomarkers to predict tumor relapse and poor clinical outcome. In this study, we correlated expression patterns of the androgen receptor (AR) coactivators lysine-specific histone demethylase 1 (LSD1) and four and a half LIM-domain protein 2 (FHL2), AR, Gleason score, Gleason grade, and p53 expression in clinically organ confined prostate cancers with relapse after radical prostatectomy. Our data reveal that high levels of LSD1, nuclear expression of the FHL2 coactivator, high Gleason score and grade, and very strong staining of nuclear p53 correlate significantly with relapse during follow-up. No correlation exists with relapse and the expression of AR and cytoplasmic expression of FHL2. To confirm these data, we did quantitative reverse transcription-PCR and Western blot analyses in a subset of tumor specimens. Consistently, both LSD1 mRNA and protein levels were significantly up-regulated in high-risk tumors. We previously identified LSD1 and FHL2 as nuclear cofactors interacting specifically with the AR in prostate cells and showed that both stimulate androgen-dependent gene transcription. Our present study suggests that LSD1 and nuclear FHL2 may serve as novel biomarkers predictive for prostate cancer with aggressive biology and point to a role of LSD1 and FHL2 in constitutive activation of AR-mediated growth signals. (Cancer Res 2006; 66(23): 11341-7)

This article has been cited by other articles:

				S. C. Wu and Y. Zhang Minireview: Role of Protein Methylation and Demethylation in Nuclear Hormone Signaling Mol. Endocrinol., September 1, 2009; 23(9): 1323 - 1334. [Abstract] [Full Text] [PDF]

				D. Z. Qian, C.-Y. Huang, C. A. O'Brien, I. M. Coleman, M. Garzotto, L. D. True, C. S. Higano, R. Vessella, P. H. Lange, P. S. Nelson, et al. Prostate Cancer-Associated Gene Expression Alterations Determined from Needle Biopsies Clin. Cancer Res., May 1, 2009; 15(9): 3135 - 3142. [Abstract] [Full Text] [PDF]

				J. X. Zou, L. Guo, A. S. Revenko, C. G. Tepper, A. T. Gemo, H.-J. Kung, and H.-W. Chen Androgen-Induced Coactivator ANCCA Mediates Specific Androgen Receptor Signaling in Prostate Cancer Cancer Res., April 15, 2009; 69(8): 3339 - 3346. [Abstract] [Full Text] [PDF]

				J. H. Schulte, S. Lim, A. Schramm, N. Friedrichs, J. Koster, R. Versteeg, I. Ora, K. Pajtler, L. Klein-Hitpass, S. Kuhfittig-Kulle, et al. Lysine-Specific Demethylase 1 Is Strongly Expressed in Poorly Differentiated Neuroblastoma: Implications for Therapy Cancer Res., March 1, 2009; 69(5): 2065 - 2071. [Abstract] [Full Text] [PDF]

				S. Bai, J. Zha, H. Zhao, F. P. Ross, and S. L. Teitelbaum Tumor Necrosis Factor Receptor-associated Factor 6 Is an Intranuclear Transcriptional Coactivator in Osteoclasts J. Biol. Chem., November 7, 2008; 283(45): 30861 - 30867. [Abstract] [Full Text] [PDF]

				H. V. Heemers, K. M. Regan, S. M. Dehm, and D. J. Tindall Androgen Induction of the Androgen Receptor Coactivator Four and a Half LIM Domain Protein-2: Evidence for a Role for Serum Response Factor in Prostate Cancer Cancer Res., November 1, 2007; 67(21): 10592 - 10599. [Abstract] [Full Text] [PDF]

				A. Scoumanne and X. Chen The Lysine-specific Demethylase 1 Is Required for Cell Proliferation in Both p53-dependent and -independent Manners J. Biol. Chem., May 25, 2007; 282(21): 15471 - 15475. [Abstract] [Full Text] [PDF]

				S. S. Nair, Z. Guo, J. M. Mueller, S. Koochekpour, Y. Qiu, R. R. Tekmal, R. Schule, H.-J. Kung, R. Kumar, and R. K. Vadlamudi Proline-, Glutamic Acid-, and Leucine-Rich Protein-1/Modulator of Nongenomic Activity of Estrogen Receptor Enhances Androgen Receptor Functions through LIM-Only Coactivator, Four-and-a-Half LIM-Only Protein 2 Mol. Endocrinol., March 1, 2007; 21(3): 613 - 624. [Abstract] [Full Text] [PDF]